Blue Earth Therapeutics

IN THE PRESS

Drug Development

Blue Earth Therapeutics Announces Promising Results of Preclinical Evaluation of 225Ac-rhPSMA-10.1 for Potential Targeted Alpha Therapy of Prostate Cancer

September 11, 2023

·

8 min read

Drug Development

Blue Earth Therapeutics Announces Results of Early Clinical and Preclinical Studies of Investigational 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer

June 28, 2023

·

9 min read

Pharm Country

Blue Earth Therapeutics Highlights Presentations at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

June 20, 2023

·

5 min read

Pharm Country

Blue Earth Therapeutics Awarded UK MHRA Innovation Passport for Investigational 177Lu-rhPSMA-10.1 for Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

November 8, 2022

·

5 min read

Drug Development

Blue Earth Therapeutics Announces Promising Results of Preclinical Biodistribution and Efficacy Evaluation of 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer

June 14, 2022

·

8 min read

FDA

Blue Earth Therapeutics Announces U.S. FDA Clearance for Investigational New Drug (IND) Application for 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer

April 12, 2022

·

5 min read

Bracco Imaging Launches New Subsidiary, Blue Earth Therapeutics, To Advance Development Of Next Generation Therapeutic Radiopharmaceutical Technology

March 1, 2022

·

5 min read

JOBS